|
|
 Previous Article | Table of Contents | Next Article 
The effect of cyclosporine A on infection of susceptible cells by human
immunodeficiency virus type 1
MA Wainberg, A Dascal, N Blain, L Fitz-Gibbon, F Boulerice, K Numazaki and M Tremblay
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewis
General Hospital, Montreal, Quebec, Canada.
The effect of cyclosporine A (CyA) on the ability of the human
immunodeficiency virus type 1 (HIV-1) to infect the H-9 T-cell leukemic
line, as well as interleukin-2 (IL-2)-grown human peripheral blood- derived
lymphocytes, has been studied. Pretreatment of H-9 cells and human
lymphocytes with CyA over 24 hours completely prevented viral infection
over a 21-day period, whereas the addition of drug at two hours
postinfection with HIV-1 had a significant inhibitory effect on viral
replication and expression of the virus-specific antigens p17 and p24.
However, if CyA was added at later times to these lymphocytic cells, this
inhibitory effect was lost. Indeed, the removal of CyA from cultures that
had been treated from two hours after infection led to the rapid production
of progeny virus. HIV-1 was able to infect peripheral blood lymphocytes
obtained from each of four kidney allograft recipients on long-term CyA
antirejection therapy, as long as drug was not included in the culture
medium. In addition, we asked what effect pretreatment with CyA of cells of
the U-937 monocytic line and primary cultures of human
monocytes/macrophages might have on infection by HIV-1. CyA had no
demonstrable effect on the ability of HIV-1 to infect cells of either type.
Volume 72,
Issue 6,
pp. 1904-1910,
12/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. G. Ptak, P. A. Gallay, D. Jochmans, A. P. Halestrap, U. T. Ruegg, L. A. Pallansch, M. D. Bobardt, M.-P. de Bethune, J. Neyts, E. De Clercq, et al.
Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent
Antimicrob. Agents Chemother.,
April 1, 2008;
52(4):
1302 - 1317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Song and C. Aiken
Analysis of Human Cell Heterokaryons Demonstrates that Target Cell Restriction of Cyclosporine-Resistant Human Immunodeficiency Virus Type 1 Mutants Is Genetically Dominant
J. Virol.,
November 1, 2007;
81(21):
11946 - 11956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hatziioannou, D. Perez-Caballero, S. Cowan, and P. D. Bieniasz
Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells
J. Virol.,
January 1, 2005;
79(1):
176 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Lawn, S. T. Butera, and T. M. Folks
Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection
Clin. Microbiol. Rev.,
October 1, 2001;
14(4):
753 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yin, D. Braaten, and J. Luban
Human Immunodeficiency Virus Type 1 Replication Is Modulated by Host Cyclophilin A Expression Levels
J. Virol.,
August 1, 1998;
72(8):
6430 - 6436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Damaso and N Moussatche
Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins
J. Gen. Virol.,
February 1, 1998;
79(2):
339 - 346.
[Abstract]
|
|
|
|
|
